Better Therapeutics- Tradeable Rights - March 2021 Other Current Liabilities

The latest other current liabilities for MCADR is $4M as of September 2023. That compares with $4.9M in the prior-year period — down 17.9% year over year. Investors often review this figure alongside Better Therapeutics- Tradeable Rights - March 2021's historical trend and sector peers before judging valuation or financial health.

Over the past year, MCADR's other current liabilities moved from $4.9M to $4M — a 17.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics- Tradeable Rights - March 2021's operating scale or balance-sheet position.

A other current liabilities figure of $4M for MCADR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MCADR's other current liabilities ($4M), review year-over-year change from $4.9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.